Guidelines for radioiodine therapy of differentiated thyroid cancer

  • M. LusterEmail author
  • S. E. Clarke
  • M. Dietlein
  • M. Lassmann
  • P. Lind
  • W. J. G. Oyen
  • J. Tennvall
  • E. Bombardieri



The purpose of the present guidelines on the radioiodine therapy (RAIT) of differentiated thyroid cancer (DTC) formulated by the European Association of Nuclear Medicine (EANM) Therapy Committee is to provide advice to nuclear medicine clinicians and other members of the DTC-treating community on how to ablate thyroid remnant or treat inoperable advanced DTC or both employing large 131-iodine (131I) activities.


For this purpose, recommendations have been formulated based on recent literature and expert opinion regarding the rationale, indications and contraindications for these procedures, as well as the radioiodine activities and the administration and patient preparation techniques to be used. Recommendations also are provided on pre-RAIT history and examinations, patient counselling and precautions that should be associated with 131I iodine ablation and treatment. Furthermore, potential side effects of radioiodine therapy and alternate or additional treatments to this modality are reviewed. Appendices furnish information on dosimetry and post-therapy scintigraphy.


Radioiodine therapy Thyroid remnant ablation Radioiodine treatment Guidelines 



beta human chorionic gonadotropin






computed tomography


differentiated thyroid carcinoma


diagnostic whole-body scan


European Association of Nuclear Medicine








131-sodium or potassium iodide






sodium iodine symporter


positron emission tomography




recombinant human thyroid-stimulating hormone


radioiodine therapy


region of interest


post-therapy whole-body scan


single photon emission computed tomography


serum thyroglobulin


thyroid hormone withdrawal or withholding


thyroid-stimulating hormone




whole-body scan


external beam radiotherapy



The authors thank Professor Furio Pacini of the University of Siena and Robert J. Marlowe for their critical reviews of the manuscript. Development of this paper was supported by a grant from Genzyme Europe B.V.


  1. 1.
    Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11(12):1093–7.PubMedGoogle Scholar
  2. 2.
    Bondeson L, Ljungberg O. Occult thyroid carcinoma at autopsy in Malmo, Sweden. Cancer 1981;47(2):319–23.PubMedGoogle Scholar
  3. 3.
    Dinneen SF, et al. Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. J Clin Endocrinol Metab. 1995;80(7):2041–5.PubMedGoogle Scholar
  4. 4.
    Durante C, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab. 2006;91(8):2892–9.PubMedGoogle Scholar
  5. 5.
    Casara D, et al. Different features of pulmonary metastases in differentiated thyroid cancer: natural history and multivariate statistical analysis of prognostic variables. J Nucl Med. 1993;34(10):1626–31.PubMedGoogle Scholar
  6. 6.
    Mazzaferri EL, Kloos RT. Clinical review 128: current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86(4):1447–63.PubMedGoogle Scholar
  7. 7.
    Eustatia-Rutten CF, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91(1):313–9.PubMedGoogle Scholar
  8. 8.
    Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med. 1998;338(5):297–306.PubMedGoogle Scholar
  9. 9.
    Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418–28.PubMedGoogle Scholar
  10. 10.
    Baudin E, Schlumberger M. New therapeutic approaches for metastatic thyroid carcinoma. Lancet Oncol. 2007;8(2):148–56.PubMedGoogle Scholar
  11. 11.
    Cancer Incidence, Mortality and Prevalence Worldwide. Cancer I.A.f.R.o. Globocan 2005.Google Scholar
  12. 12.
    Pacini F, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787–803.PubMedGoogle Scholar
  13. 13.
    Cooper DS, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006;16(2):109–42.PubMedGoogle Scholar
  14. 14.
    Rodrigues F, et al. [Treatment and follow up protocol in differentiated thyroid carcinomas of follicular origin]. Acta Med Port. 2005;18(1):2–16.PubMedGoogle Scholar
  15. 15.
    Dietlein M, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin 2007;46(5):213–9.PubMedGoogle Scholar
  16. 16.
    Franzius C, et al. Procedure guideline for radioiodine therapy and (131)iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. Nuklearmedizin 2007;46(5):224–31.PubMedGoogle Scholar
  17. 17.
    Trattamento e Follow-up del Carcinoma Tiroideo Differenziato della Tiroide. Linee Guida SIE-AIMN-AIFM. 2004;1–75.Google Scholar
  18. 18.
    Links TP, et al. [Guideline ‘Differentiated thyroid carcinoma’, including diagnosis of thyroid nodules]. Ned Tijdschr Geneeskd. 2007;151(32):1777–82.PubMedGoogle Scholar
  19. 19.
    Guidelines for the Management of Thyroid Cancer in Adults, ed. P.U.o.t.R.C.o. Physicians. 2002, London, UK: British Thyroid Association and Royal College of Physicians.Google Scholar
  20. 20.
    Sawka AM, et al. Clinical review 170: a systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab. 2004;89(8):3668–76.PubMedGoogle Scholar
  21. 21.
    Pacini F, et al. Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol. 2005;153(5):651–9.PubMedGoogle Scholar
  22. 22.
    Pacini F, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2006;91(3):926–32.PubMedGoogle Scholar
  23. 23.
    Pilli T, et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab. 2007;92(9):3542–6.PubMedGoogle Scholar
  24. 24.
    Hay ID, et al. Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg. 2002;26(8):879–85.PubMedGoogle Scholar
  25. 25.
    Chow SM, et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98(1):31–40.PubMedGoogle Scholar
  26. 26.
    Pelizzo MR, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a mono-institutional 12-year experience. Nucl Med Commun. 2004;25(6):547–52.PubMedGoogle Scholar
  27. 27.
    Robbins RJ, et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J Clin Endocrinol Metab. 2006;91(2):498–505.PubMedGoogle Scholar
  28. 28.
    Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82(11):3637–42.PubMedGoogle Scholar
  29. 29.
    Besic N, et al. The role of radioactive iodine in the treatment of Hürthle cell carcinoma of the thyroid. Thyroid 2003;13(6):577–84.PubMedGoogle Scholar
  30. 30.
    Berg G, et al. Radioiodine ablation and therapy in differentiated thyroid cancer under stimulation with recombinant human thyroid-stimulating hormone. J Endocrinol Investig. 2002;25(1):44–52.Google Scholar
  31. 31.
    Sandeep TC, et al. Second primary cancers in thyroid cancer patients: a multinational record linkage study. J Clin Endocrinol Metab. 2006;91(5):1819–25.PubMedGoogle Scholar
  32. 32.
    Hackshaw A, et al. 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92(1):28–38.PubMedGoogle Scholar
  33. 33.
    Jarzab B, Handkiewicz-Junak D, Wloch J. Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. Endocr Relat Cancer. 2005;12(4):773–803.PubMedGoogle Scholar
  34. 34.
    Reynolds J. Comparison of I-131 absorbed radiation doses in children and adults: a tool for estimating therapeutic I-131 doses in children. In: Robbins J, editor. Treatment of thyroid cancer in children. Washington, DC: US Department of Energy and US Department of Commerce, Technology, Administration, National Technical Information; 1993. p. 127–35.Google Scholar
  35. 35.
    Leeper RD. The effect of 131 I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. J Clin Endocrinol Metab. 1973;36(6):1143–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Beierwaltes WH, et al. Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. J Nucl Med. 1982;23(7):561–8.PubMedGoogle Scholar
  37. 37.
    Bernier MO, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2001;86(4):1568–73.PubMedGoogle Scholar
  38. 38.
    Pacini F, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg. 1994;18(4):600–4.PubMedGoogle Scholar
  39. 39.
    Song H, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47(12):1985–94.PubMedGoogle Scholar
  40. 40.
    Sisson JC, Carey JE. Thyroid carcinoma with high levels of function: treatment with (131)I. J Nucl Med. 2001;42(6):975–83.PubMedGoogle Scholar
  41. 41.
    Maxon HR 3rd, et al. Radioiodine-131 therapy for well-differentiated thyroid cancer—a quantitative radiation dosimetric approach: outcome and validation in 85 patients. J Nucl Med. 1992;33(6):1132–6.PubMedGoogle Scholar
  42. 42.
    Benua RS, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. Am J Roentgenol Radium Ther Nucl Med. 1962;87:171–82.PubMedGoogle Scholar
  43. 43.
    Freudenberg L, Jentzen W, Goerges R, Petrich T, Marlowe RJ, Knust J, Bockisch A. 124I-PET dosimetry in advanced differentiated thyroid cancer. Therapeutic impact. Nuklearmedizin 2007;46:121–8.PubMedGoogle Scholar
  44. 44.
    Lassmann M, Hänscheid H, Chiesa C, Hindorf C, Flux G, Luster M. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. Eur J Nucl Med Mol Imaging. 2008;35(7):1405–12. doi: 10.1007/s00259-008-0761-x.PubMedGoogle Scholar
  45. 45.
    Murcutt G, et al. Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy. Kidney Int. 2008;73(11):1316–9.PubMedGoogle Scholar
  46. 46.
    Alevizaki C, et al. Iodine 131 treatment for differentiated thyroid carcinoma in patients with end stage renal failure: dosimetric, radiation safety, and practical considerations. Hormones (Athens) 2006;5(4):276–87.Google Scholar
  47. 47.
    Duntas LH, Biondi B. Short-term hypothyroidism after levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. Eur J Endocrinol. 2007;156(1):13–9.PubMedGoogle Scholar
  48. 48.
    Luster M, et al. Thyroid hormone withdrawal in patients with differentiated thyroid carcinoma: a one hundred thirty-patient pilot survey on consequences of hypothyroidism and a pharmacoeconomic comparison to recombinant thyrotropin administration. Thyroid 2005;15(10):1147–55.PubMedGoogle Scholar
  49. 49.
    Dow KH, Ferrell BR, Anello C. Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 1997;7(4):613–9.PubMedGoogle Scholar
  50. 50.
    Schroeder PR, et al. A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab. 2006;91(3):878–84.PubMedGoogle Scholar
  51. 51.
    Botella-Carretero JI, et al. Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2003;10(4):601–10.PubMedGoogle Scholar
  52. 52.
    Botella-Carretero JI, et al. Chronic thyrotropin-suppressive therapy with levothyroxine and short-term overt hypothyroidism after thyroxine withdrawal are associated with undesirable cardiovascular effects in patients with differentiated thyroid carcinoma. Endocr Relat Cancer. 2004;11(2):345–56.PubMedGoogle Scholar
  53. 53.
    Botella-Carretero JI, et al. The effects of thyroid hormones on circulating markers of cell-mediated immune response, as studied in patients with differentiated thyroid carcinoma before and during thyroxine withdrawal. Eur J Endocrinol. 2005;153(2):223–30.PubMedGoogle Scholar
  54. 54.
    Botella-Carretero JI, et al. Effects of thyroid hormones on serum levels of adipokines as studied in patients with differentiated thyroid carcinoma during thyroxine withdrawal. Thyroid 2006;16(4):397–402.PubMedGoogle Scholar
  55. 55.
    Billewicz WZ, et al. Statistical methods applied to the diagnosis of hypothyroidism. Q J Med. 1969;38(150):255–66.PubMedGoogle Scholar
  56. 56.
    Tagay S, et al. Health-related quality of life, anxiety and depression in thyroid cancer patients under short-term hypothyroidism and TSH-suppressive levothyroxine treatment. Eur J Endocrinol. 2005;153(6):755–63.PubMedGoogle Scholar
  57. 57.
    Ladenson PW, et al. Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med. 1997;337(13):888–96.PubMedGoogle Scholar
  58. 58.
    Haugen BR, et al. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab. 1999;84(11):3877–85.PubMedGoogle Scholar
  59. 59.
    Borget I, et al. Sick leave for follow-up control in thyroid cancer patients: comparison between stimulation with Thyrogen and thyroid hormone withdrawal. Eur J Endocrinol. 2007;156(5):531–8.PubMedGoogle Scholar
  60. 60.
    Nijhuis TF, van Wepperen W, de Klerk JMH. Costs associated with the withdrawal of thyroid hormone suppression therapy during the follow-up treatment of well-differentiated thyroid cancer. Tijd Nucl Geneeskd. 1999;21:98–100.Google Scholar
  61. 61.
    Leclere J, Nunez S, Dejaz C, Sohmer V, Schvartz C. Quantitative and qualitative consequences of l-T4 suppressive withdrawal. 3 September 2000: Satellite Symposium Presentation, EANM Annual Congress, Paris, France.Google Scholar
  62. 62.
    Grigsby PW, et al. Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1–3 weeks of thyroxine discontinuation. J Nucl Med. 2004;45(4):567–70.PubMedGoogle Scholar
  63. 63.
    Kuijt WJ, Huang SA. Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. J Clin Endocrinol Metab. 2005;90(11):6123–5.PubMedGoogle Scholar
  64. 64.
    Luster M. Acta Oncologica Lecture. Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncol. 2006;45(8):1018–30.PubMedGoogle Scholar
  65. 65.
    Tuttle RM, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med. 2008;49(5):764–70.PubMedGoogle Scholar
  66. 66.
    Barbaro D, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab. 2003;88(9):4110–5.PubMedGoogle Scholar
  67. 67.
    Barbaro D, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nucl Med Commun. 2006;27(8):627–32.PubMedGoogle Scholar
  68. 68.
    Pacini F, et al. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab. 2002;87(9):4063–8.PubMedGoogle Scholar
  69. 69.
    Luster M, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer. 2005;12(1):49–64.PubMedGoogle Scholar
  70. 70.
    Robbins RJ, Driedger A, Magner J. Recombinant human thyrotropin-assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 2006;16(11):1121–30.PubMedGoogle Scholar
  71. 71.
    de Keizer B, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. Eur J Nucl Med Mol Imaging. 2003;30(3):367–73.PubMedGoogle Scholar
  72. 72.
    Taieb D, Lussato D, Mundler O. Subcutaneous administration of recombinant human thyrotropin as an alternative to thyroid hormone withdrawal in patients with anticoagulated thyroid cancer: preliminary results. Thyroid 2004;14(6):463–4.PubMedGoogle Scholar
  73. 73.
    Hänscheid H, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med. 2006;47(4):648–54.PubMedGoogle Scholar
  74. 74.
    Vaiano A, et al. Comparison between remnant and red-marrow absorbed dose in thyroid cancer patients submitted to 131I ablative therapy after rh-TSH stimulation versus hypothyroidism induced by l-thyroxine withdrawal. Nucl Med Commun. 2007;28(3):215–23.PubMedGoogle Scholar
  75. 75.
    Borget I, Schlumberger M, Allyn M, De Pouvoirville G, Remy H, Ricard M. Radioiodine ablation in thyroid cancer patients: comparison of length and cost of hospital stay between preparation by thyroid hormone withdrawal and Thyrogen. Eur J Endocrinol 2008; in press.Google Scholar
  76. 76.
    Pluijmen MJ, et al. Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin Endocrinol (Oxf). 2003;58(4):428–35.Google Scholar
  77. 77.
    Maxon HR, et al. Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med. 1983;309(16):937–41.PubMedGoogle Scholar
  78. 78.
    Pentlow KS, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med. 1996;37(9):1557–62.PubMedGoogle Scholar
  79. 79.
    Sgouros G, et al. Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software. J Nucl Med. 2004;45(8):1366–72.PubMedGoogle Scholar
  80. 80.
    Mandel SJ, Mandel L. Radioactive iodine and the salivary glands. Thyroid. 2003;13(3):265–71.PubMedGoogle Scholar
  81. 81.
    Nakada K, et al. Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med. 2005;46(2):261–6.PubMedGoogle Scholar
  82. 82.
    Berg G, et al. Consequences of inadvertent radioiodine treatment of Graves’ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing? Acta Oncol. 2008;47(1):145–9.PubMedGoogle Scholar
  83. 83.
    Schlumberger M, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med. 1996;37(4):606–12.PubMedGoogle Scholar
  84. 84.
    Ceccarelli C, et al. 131I therapy for differentiated thyroid cancer leads to an earlier onset of menopause: results of a retrospective study. J Clin Endocrinol Metab. 2001;86(8):3512–5.PubMedGoogle Scholar
  85. 85.
    Krassas GE, Perros P. Thyroid disease and male reproductive function. J Endocrinol Investig. 2003;26(4):372–80.Google Scholar
  86. 86.
    Kolbert KS, et al. Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software. J Nucl Med. 2007;48(1):143–9.PubMedGoogle Scholar
  87. 87.
    Mattavelli F, et al. Role of surgery in treatment of advanced differentiated thyroid carcinomas. Acta Otorhinolaryngol Ital. 2007;27(2):62–7.PubMedGoogle Scholar
  88. 88.
    Shimaoka K, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56(9):2155–60.PubMedGoogle Scholar
  89. 89.
    Williams SD, Birch R, Einhorn LH. Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer Treat Rep. 1986;70(3):405–7.PubMedGoogle Scholar
  90. 90.
    Santini F, et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab. 2002;87(9):4160–5.PubMedGoogle Scholar
  91. 91.
    Tubiana M, et al. External radiotherapy in thyroid cancers. Cancer 1985;55(9 Suppl):2062–71.PubMedGoogle Scholar
  92. 92.
    Biermann M, et al. Guidelines on radioiodine therapy for differentiated thyroid carcinoma: impact on clinical practice. Nuklearmedizin 2005;44(6):229–34. 236–7.PubMedGoogle Scholar
  93. 93.
    Rosenbluth BD, et al. Intensity-modulated radiation therapy for the treatment of nonanaplastic thyroid cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1419–26.PubMedGoogle Scholar
  94. 94.
    Marples B, et al. Low-dose hyper-radiosensitivity: a consequence of ineffective cell cycle arrest of radiation-damaged G2-phase cells. Radiat Res. 2004;161(3):247–55.PubMedGoogle Scholar
  95. 95.
    Keum KC, et al. The role of postoperative external-beam radiotherapy in the management of patients with papillary thyroid cancer invading the trachea. Int J Radiat Oncol Biol Phys. 2006;65(2):474–80.PubMedGoogle Scholar
  96. 96.
    Meadows KM, et al. External beam radiotherapy for differentiated thyroid cancer. Am J Otolaryngol. 2006;27(1):24–8.PubMedGoogle Scholar
  97. 97.
    Mazzarotto R, et al. The role of external beam radiotherapy in the management of differentiated thyroid cancer. Biomed Pharmacother. 2000;54(6):345–9.PubMedGoogle Scholar
  98. 98.
    Brierley JD, Tsang RW. External-beam radiation therapy in the treatment of differentiated thyroid cancer. Semin Surg Oncol. 1999;16(1):42–9.PubMedGoogle Scholar
  99. 99.
    Biermann M. External beam radiotherapy. In: Biersack HJ, Gruenwald F, editors. Thyroid cancer. Heidelberg: Springer; 2005. p. 139–61.Google Scholar
  100. 100.
    Oyen W, et al. Targeted therapy in nuclear medicine—current status and future prospects. Ann Oncol 2007. 1782–92.Google Scholar
  101. 101.
    Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Curr Drug Targets Immune Endocr Metabol Disord. 2004;4(3):175–80.PubMedGoogle Scholar
  102. 102.
    Simon D, et al. Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging. 2002;29(6):775–82.PubMedGoogle Scholar
  103. 103.
    Schmutzler C. Regulation of the sodium/iodide symporter by retinoids—a review. Exp Clin Endocrinol Diabetes. 2001;109(1):41–4.PubMedGoogle Scholar
  104. 104.
    Liu YY, et al. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol. 2006;154(4):525–31.PubMedGoogle Scholar
  105. 105.
    Zhang Y, et al. A clinical study of all-trans-retinoid-induced differentiation therapy of advanced thyroid cancer. Nucl Med Commun. 2007;28(4):251–5.PubMedGoogle Scholar
  106. 106.
    Cramer M, Luster M, Fuehrer D, Schmutzler C, Beer M, Morganthaler NG, et al. Retinsäurebehandlung und Verlauf eines initial nicht iodaviden gering differenzierten Schilddrüsenkarzinoms bei einer Patientin mit TSH-Rezeptor-blockierenden Antikörpern. Nuklearmedizin 2008;47:N25–8.Google Scholar
  107. 107.
    Tharp K, Israel O, Hausmann J, Bettman L, Martin WH, Daitzchman M, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2004;31:1435–442.PubMedGoogle Scholar
  108. 108.
    Hyer S, et al. Salivary gland toxicity after radioiodine therapy for thyroid cancer. Clin Oncol (R Coll Radiol). 2007;19(1):83–6.Google Scholar
  109. 109.
    Hyer S, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol (Oxf). 2002;56(6):755–8.Google Scholar
  110. 110.
    Wichers M, et al. Testicular function after radioiodine therapy for thyroid carcinoma. Eur J Nucl Med. 2000;27(5):503–7.PubMedGoogle Scholar
  111. 111.
    Reiners C, Lassmann M, Hanscheid H. A perspective on post-Chernobyl radioablation in young females. J Nucl Med. 2006;47(10):1563–4.PubMedGoogle Scholar
  112. 112.
    Rubino C, et al. Second primary malignancies in thyroid cancer patients. Br J Cancer. 2003;89(9):1638–44.PubMedGoogle Scholar
  113. 113.
    de Vathaire F, et al. Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer. 1997;75(5):734–9.PubMedGoogle Scholar
  114. 114.
    Chen AY, et al. The development of breast carcinoma in women with thyroid carcinoma. Cancer 2001;92(2):225–31.PubMedGoogle Scholar
  115. 115.
    Maxon HR 3rd, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am. 1990;19(3):685–718.PubMedGoogle Scholar
  116. 116.
    Siegel JA, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S–61S.PubMedGoogle Scholar
  117. 117.
    Snyder W, Ford MR, Warner GG, et al. MIRD pamphlet no. 11: S, absorbed dose per unit cumulated activity for selected radionuclides and organs. New York, NY: Society of Nuclear Medicine; 1975.Google Scholar
  118. 118.
    Dietlein M, et al. [Procedure guideline for radioiodine test (version 3)]. Nuklearmedizin 2007;46(5):198–202.PubMedGoogle Scholar
  119. 119.
    Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med. 2005;46(6):1023–7.PubMedGoogle Scholar
  120. 120.
    Menzel C, et al. “High-dose” radioiodine therapy in advanced differentiated thyroid carcinoma. J Nucl Med. 1996;37(9):1496–503.PubMedGoogle Scholar
  121. 121.
    Crawford DC, et al. Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography. Eur J Nucl Med. 1997;24(12):1470–8.PubMedGoogle Scholar
  122. 122.
    Eschmann SM, et al. Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET. Eur J Nucl Med Mol Imaging. 2002;29(6):760–7.PubMedGoogle Scholar
  123. 123.
    Lassmann M, et al. Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. J Nucl Med. 2004;45(4):619–25.PubMedGoogle Scholar
  124. 124.
    Leeper RD. Thyroid cancer. Med Clin North Am. 1985;69(5):1079–96.PubMedGoogle Scholar
  125. 125.
    Luster M, et al. Comparison of radioiodine biokinetics following the administration of recombinant human thyroid stimulating hormone and after thyroid hormone withdrawal in thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2003;30(10):1371–7.PubMedGoogle Scholar
  126. 126.
    Thomas SR, et al. Predictive estimate of blood dose from external counting data preceding radioiodine therapy for thyroid cancer. Nucl Med Biol. 1993;20(2):157–62.PubMedGoogle Scholar
  127. 127.
    Medvedec M. Thyroid stunning in vivo and in vitro. Nucl Med Commun. 2005;26(8):731–5.PubMedGoogle Scholar
  128. 128.
    Tuttle RM, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. J Nucl Med. 2006;47(10):1587–91.PubMedGoogle Scholar
  129. 129.
    Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med. 1998;39(9):1531–6.PubMedGoogle Scholar

Copyright information

© EANM 2008

Authors and Affiliations

  • M. Luster
    • 1
    Email author
  • S. E. Clarke
    • 2
  • M. Dietlein
    • 3
  • M. Lassmann
    • 1
  • P. Lind
    • 4
  • W. J. G. Oyen
    • 5
  • J. Tennvall
    • 6
  • E. Bombardieri
    • 7
  1. 1.Department of Nuclear MedicineUniversity of WürzburgWürzburgGermany
  2. 2.Guys and St. Thomas HospitalLondonUK
  3. 3.Department of Nuclear MedicineUniversity of CologneCologneGermany
  4. 4.Department of Nuclear Medicine and EndocrinologyPositron Emission Tomography/Computed Tomography CentreKlagenfurtAustria
  5. 5.Radboud University Nijmegen Medical CentreNijmegenThe Netherlands
  6. 6.Department of OncologyLund University HospitalLundSweden
  7. 7.National Cancer Institute FoundationMilanItaly

Personalised recommendations